University Hospital Münster

Running trials

• Not yet recruiting

  A Study to Learn How Well People With Bronchiectasis Tolerate Continued Treatment With Verducatib After Earlier Studies (AIRTIVITY®-ON)

  NCT07915219· Phase 3· Boehringer Ingelheim· Source

• Not yet recruiting

  Within-Session Repeatability of EUS-Guided Portal Pressure Gradient Measurement

  NCT07877298· University Hospital Muenster· Source

• Recruiting

  Endohepatology-Based Reclassification of Treatment Indication in High-Risk MASLD

  NCT07877272· University Hospital Muenster· Source

• Not yet recruiting

  Catheter Ablation for AF in Patients With Severe Mitral Regurgitation After Successful Transcatheter Mitral-Valve Repair

  NCT07380932· Atrial Fibrillation Network· Source

• Recruiting

  Registry for Duchenne and Becker Muscular Dystrophy

  NCT07402122· Dr. Andreas Ziegler· Source

• Recruiting

  Biomechanical Effects of EMST® on Swallowing Function in Parkinson's Disease

  NCT07606547· University Hospital Muenster· Source

• Recruiting

  ToPanc Trial: Survival After Total Versus Partial Pancreaticoduodenectomy for Adenocarcinoma of the Pancreatic Head, Distal Cholangiocarcinoma, and Ampullary Cancer

  NCT06801899· Insel Gruppe AG, University Hospital Bern· Source

• Recruiting

  A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )

  NCT07101328· Phase 1· Eli Lilly and Company· Source

• Recruiting

  A Phase 2b Study of the Effects of Camoteskimab in Adults With Moderate-to-Severe Atopic Dermatitis

  NCT07599813· Phase 2· Apollo Therapeutics Ltd· Source

• Recruiting

  Establishing a Reference Framework for Outcomes After Machine-Preserved Liver Transplantation in Europe

  NCT07585890· University Medical Center Groningen· Source

• Recruiting

  Mental Health and Suicidality in Glioblastoma Patients in Germany

  NCT07409584· University Hospital, Essen· Source

• Recruiting

  Subcutaneous Immunoglobulin Therapy Effectiveness Monitoring in CIDP Patients Using Smart Devices

  NCT07273903· Heinrich-Heine University, Duesseldorf· Source

• Recruiting

  Study of Cabozantinib in Participants With Neuroendocrine Tumors Who Have Already Received Prior Treatment

  NCT07314164· Ipsen· Source

• Recruiting

  A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract

  NCT07218380· Phase 3· Eli Lilly and Company· Source

• Recruiting

  Study on chemotherapy and experimental drugs in patients with Philadelphia Chromosome positive and ABL-class Philadelphia Chromosome-Like B-cell Acute Lymphoblastic Leukemia

  2025-520982-39-00· Phase 3· Universita Degli Studi Di Milano Bicocca· Source

• Recruiting

  A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer

  NCT06793215· Phase 3· Hoffmann-La Roche· Source

• Recruiting

  CLEOPATTRA: A Research Study to Look at the Effects of Treatment With a Medicine Called Coramitug (NNC6019-0001) in People With Heart Failure Due to Transthyretin Amyloid (ATTR) Amyloidosis

  NCT07207811· Phase 3· Novo Nordisk A/S· Source

• Recruiting

  European Multi-Centre Post-Market Registry on Thoracic Endovascular Arch Repair Using Castor™ and Cratos™

  NCT07668687· Shanghai MicroPort Endovascular MedTech（Group）Co., Ltd· Source

• Active, not recruiting

  Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity

  NCT07037433· Phase 3· Amgen· Source

• Recruiting

  The AIRTIVITY™ Study: A Study to Find Out Whether BI 1291583 Helps People With Bronchiectasis

  NCT06872892· Phase 3· Boehringer Ingelheim· Source

• Recruiting

  A Study to Evaluate the Efficacy, Safety and Tolerability of BMS-986368 in Participants With Multiple Sclerosis Spasticity

  NCT06782490· Phase 2· Celgene· Source

• Active, not recruiting

  A Study to Evaluate Axatilimab Versus Best Available Therapy in Participants With Chronic Graft Versus Host Disease After at Least 2 Prior Lines of Systemic Therapy

  NCT06821542· Phase 3· Incyte Corporation· Source

• Recruiting

  Video-Tumorboard PLUS

  NCT06980740· University Hospital Muenster· Source

• Recruiting

  Multicenter Trial on Surgical Outcome and Quality of Life in Juxta-medullary Tumors

  NCT07056023· University Hospital Muenster· Source

• Recruiting

  Gilteritinib in Combination With Venetoclax and Azacitidine for AML Patients With FLT3 Mutations Ineligible for Intensive Treatment

  NCT06696183· Phase 2· Technische Universität Dresden· Source

• Active, not recruiting

  Post Market Registry for GORE® TAG® Thoracic Branch Endoprosthesis

  NCT06507865· W.L.Gore & Associates· Source

• Recruiting

  A Study to Evaluate Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease

  NCT06585774· Phase 3· Incyte Corporation· Source

• Active, not recruiting

  A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2)

  NCT06516965· Phase 3· Incyte Corporation· Source

• Recruiting

  A Study to Investigate Effects of Ocrelizumab Treatment on Neurofilament Light Chain (NfL) Levels and Participant Satisfaction in Participants With Multiple Sclerosis (MS)

  NCT06780150· Hoffmann-La Roche· Source

• Recruiting

  Prediction of Decompensation and HCC Development in Advanced Chronic Liver Disease

  NCT06523608· University Hospital Muenster· Source

• Recruiting

  Semibranch Registry - Retrospective

  NCT06374355· University Hospital Muenster· Source

• Recruiting

  Severe Complications During Ventricular Tachycardia or Premature Ventricular Complex Ablation

  NCT07777744· University Hospital, Basel, Switzerland· Source

• Recruiting

  Diagnostic Performance of [18F]PSMA-1007 PET/CT Imaging in Patients With Newly-Diagnosed Prostate Cancer

  NCT06122584· Phase 3· ABX advanced biochemical compounds GmbH· Source

• Recruiting

  CARE1: FIRST LINE RANDOMISED STUDY PLATFORM TO OPTIMIZE TREATMENT IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA

  2023-503317-29-00· Phase 3· Institut Gustave Roussy· Source

• Recruiting

  Phase 3 Clinical Trial With Dapagliflozin in Chronic Kidney Disease in Adolescents and Young Adult Patients

  NCT05944016· Phase 3· University Hospital Goettingen· Source

• Recruiting

  Personalized Long-term Human Albumin Treatment in Patients With Decompensated Cirrhosis and Ascites

  NCT05056220· Phase 3· Aleksander Krag· Source

• Recruiting

  Intravenous Fish Oil Based Lipid Emulsion to Enhance Recovery in High-Risk Cardiac Surgery Patients

  NCT06279793· Phase 2· GCP-Service International West GmbH· Source

• Recruiting

  Correlation of Cardiac Output Determined by Echocardiography and Indirect Calorimetry in Critically Ill Patients in Cardiogenic Shock on Extracorporeal Circulatory Life Support

  NCT06369818· Universität Münster· Source

• Recruiting

  Outcome of the Semibranch in Pararenal and Thoracoabdominal Aortic Pathologies. A Prospective, Multicentre Registry.

  NCT06059053· University Hospital Muenster· Source

• Active, not recruiting

  Systematic Assessment of Treatment Effectiveness for Long-Term Management of Stable Atrial Tachycardia in Inpatient and Outpatient Environments

  NCT07239804· Evangelical Hospital Düsseldorf· Source

• Recruiting

  Intensified treatment in patients with oligometastatic pancreatic cancer - multimodal surgical treatment versus systemic chemotherapy alone: a randomized controlled trial - METAPANC

  2023-503558-10-00· Phase 3· Universitaetsmedizin Goettingen· Source

• Active, not recruiting

  German Observational Multicenter Study of Patients With Fabry Disease Under Enzyme Replacement Therapy With Pegunigalsidase-alfa

  NCT06095713· Universität Münster· Source

• Active, not recruiting

  Study of Lurbinectedin in Combination With Doxorubicin Versus Doxorubicin Alone as First-line Treatment in Participants With Metastatic Leiomyosarcoma (SaLuDo)

  NCT06088290· Phase 3· PharmaMar· Source

• Recruiting

  A Study to Evaluate the Safety, Efficacy, PK, PD and Immunogenicity of Cipaglucosidase Alfa/Miglustat in IOPD Subjects Aged 0 to <18

  NCT04808505· Phase 3· Amicus Therapeutics· Source

• Active, not recruiting

  Real World Data Collection in Subjects Treated With the FARAPULSE Pulsed Field Ablation System

  NCT05501873· Boston Scientific Corporation· Source

• Enrolling by invitation

  A Study to Assess the Long-Term Safety and Efficacy of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis

  NCT05735483· Phase 3· Eli Lilly and Company· Source

• Recruiting

  Post-market European & Asian Registry to Evaluate the Minos™ Stent-Graft and Delivery System in Abdominal Aortic Aneurysm Treatment

  NCT07674173· Shanghai MicroPort Endovascular MedTech（Group）Co., Ltd· Source

• Recruiting

  Non-interventional Study of Seroprevalence of Pre-existing Antibodies Against Adenovirus-associated Virus Vector (AAV9) and the Progression of Disease in Patients With Plakophilin 2 (PKP2)-Associated Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC)

  NCT06311708· Tenaya Therapeutics· Source

• Active, not recruiting

  Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer (TROPION-Lung07)

  NCT05555732· Phase 3· Daiichi Sankyo· Source

• Enrolling by invitation

  An Extension Study to Assess Long-Term Safety of Eplontersen in Adults With Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM)

  NCT05667493· Phase 3· Ionis Pharmaceuticals, Inc.· Source

Showing 50 of 96.

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Childhood cancers6 recruiting
• Aortic aneurysm4 recruiting
• Liver cirrhosis4 recruiting
• Atrial fibrillation3 recruiting
• Glioblastoma3 recruiting
• Heart failure3 recruiting
• Parkinson disease3 recruiting
• Acute lymphoblastic leukaemia2 recruiting
• Acute myeloid leukaemia2 recruiting
• Amyloidosis2 recruiting
• Bronchiectasis2 recruiting
• High blood pressure2 recruiting
• Liver and biliary tract cancer2 recruiting
• Multiple sclerosis2 recruiting
• Pancreatic cancer2 recruiting
• Prostate cancer2 recruiting
• Atopic dermatitis (eczema)1 recruiting
• Bladder cancer1 recruiting
• Chronic kidney disease1 recruiting
• CIDP (chronic inflammatory demyelinating polyneuropathy)1 recruiting
• Depression1 recruiting
• Duchenne muscular dystrophy1 recruiting
• Dystonia1 recruiting
• Essential tremor1 recruiting
• Fatty liver disease (MASLD/MASH)1 recruiting
• Follicular lymphoma1 recruiting
• Gastric and oesophageal cancer1 recruiting
• Hypertrophic cardiomyopathy1 recruiting
• Kidney cancer1 recruiting
• Lung cancer1 recruiting
• Mantle cell lymphoma1 recruiting
• Melanoma1 recruiting
• Meningioma1 recruiting
• Multiple system atrophy1 recruiting
• Neuroblastoma1 recruiting
• Neuroendocrine tumours1 recruiting
• Pompe disease1 recruiting
• Rheumatoid arthritis1 recruiting
• Stroke1 recruiting
• Ventricular tachycardia1 recruiting

Closed trials

• Completed

  Inferior Vena Cava Pressure as Alternative to Hepatic Venous Pressure for EUS-guided Portal Pressure Gradient Measurement

  NCT07703540· University Hospital Muenster· Source

• Completed

  Validation of New Prognostic Biomarkers in Patients With Decompensated Cirrhosis

  NCT06855056· European Foundation for Study of Chronic Liver Failure· Source

• Completed

  Clinical Trial Evaluating Safety of 5-Aminolevulinic Acid (5-ALA) Combined With CV01 Delivery of Ultrasound for Sonodynamic Therapy (SDT) in Patients With Newly Diagnosed High-Grade Glioma (HGG) Prior to Resection and Standard Adjuvant Therapy (ALA SDT GLIOMA 401)

  NCT06665724· Phase 1· Universität Münster· Source

• Completed

  Terlipressin in Combined Hepatorenal Syndrome in Patients With Signs of Chronic Renal Disease

  NCT06161766· University Hospital Freiburg· Source

• Completed

  Implementing Spiritual Care in Inpatient Palliative Care

  NCT06206551· University Hospital Muenster· Source

• Completed

  Patient Reported Outcomes In Liver Biopsy (EUS vs. Percutaneous)

  NCT07506642· University Hospital Muenster· Source

• Completed

  A Study for the Participants With Metastatic Hormone Sensitive Prostate Cancer (mHSPC) Treated With Androgen Deprivation Therapy (ADT) Plus Apalutamide or Enzalutamide

  NCT05901649· Janssen-Cilag Ltd.· Source

• Completed

  To Investigate Efficacy, Pharmacodynamics, and Safety of BC 007 in Participants With Long COVID

  NCT05911009· Phase 2· Berlin Cures GmbH· Source

• Completed

  Efficacy and Safety Study of HRO350 in Patients with Mild-to-moderate Psoriasis (the 'HeROPA' Study).

  NCT06125808· Phase 2· Arctic Bioscience· Source

• Completed

  Safety and Efficacy of Intra-arterial Tenecteplase for Noncomplete Reperfusion of Intracranial Occlusions

  NCT05499832· Phase 3· Insel Gruppe AG, University Hospital Bern· Source

• Completed

  Electronic Monitoring of Disease Activity in Patients With Chronic Inflammatory Demyelinating Polyneuropathy

  NCT05723848· Heinrich-Heine University, Duesseldorf· Source

• Completed

  BOLT Lithotripsy RESTORE ATK Trial

  NCT05662787· Bolt Medical· Source

• Completed

  Assessing EUS and Percutaneous Untargeted Liver Biopsy Quality

  NCT07701031· University Hospital Muenster· Source

• Completed

  A Study Assessing Rocatinlimab (AMG 451) Monotherapy in Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-Horizon)

  NCT05651711· Phase 3· Amgen· Source

• Completed

  A Phase 3 Study of Telitacicept for the Treatment of Moderately to Severely Active Systemic Lupus Erythematosus

  NCT05306574· Phase 3· Remegen Co. Ltd.· Source

• Completed

  A Study to Evaluate Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis

  NCT05601882· Phase 3· AbbVie· Source

• Terminated

  A Study of Etavopivat for the Treatment of Anemia in Patients With Myelodysplastic Syndromes (MDS)

  NCT05568225· Phase 2· Forma Therapeutics, Inc.· Source

• Completed

  Effects of Aerobic Exercise During the Early Rehabilitation After Ischemic Stroke

  NCT05690165· University Hospital Muenster· Source

• Completed

  Effects of Triptorelin When Given Every 6-months Under the Skin to Adult Males With Cancer in the Prostate

  NCT05458856· Phase 3· Ipsen· Source

• Completed

  A Double-blind Study to Investigate Efficacy and Safety of Buntanetap Compared With Placebo in Participants With Early PD

  NCT05357989· Phase 3· Annovis Bio Inc.· Source

• Terminated

  A Study to Test Whether BI 685509 Alone or in Combination With Empagliflozin Helps People With Liver Cirrhosis Caused by Viral Hepatitis or Non-alcoholic Steatohepatitis (NASH) Who Have High Blood Pressure in the Portal Vein (Main Vessel Going to the Liver)

  NCT05282121· Phase 2· Boehringer Ingelheim· Source

• Terminated

  A Study to Test Whether Two Different Doses of Avenciguat Help People With Liver Cirrhosis and High Blood Pressure in the Portal Vein (Main Vessel Going to the Liver)

  NCT05161481· Phase 2· Boehringer Ingelheim· Source

• Recruiting

  ADT +/- Darolutamide in de Novo Metastatic Prostate Cancer Patients With Vulnerable Functional Ability (PEACE6-Vulnerable)

  NCT04916613· Phase 3· UNICANCER· Source

• Terminated

  A Study To Evaluate Efficacy, Safety, Pharmacokinetics, And Pharmacodynamics Of Satralizumab In Patients With Generalized Myasthenia Gravis

  NCT04963270· Phase 3· Hoffmann-La Roche· Source

• Terminated

  directSTIM™ Deep Brain Stimulation System Post-Market Clinical Follow-up Study on Essential Tremor

  NCT05795218· Aleva Neurotherapeutics SA· Source

• Recruiting

  RESTORE - Study of AGN1 LOEP to Prevent Secondary Hip Fractures

  NCT04796350· AgNovos Healthcare, LLC· Source

• Completed

  A Study to Evaluate the Long-Term Safety and Tolerability of Faricimab in Participants With Neovascular Age-Related Macular Degeneration

  NCT04777201· Phase 3· Hoffmann-La Roche· Source

• Completed

  Self Tonometry and Transfer of Glaucoma Patients' Data for Improving the Supply Situation

  NCT04698876· University Hospital Muenster· Source

• Completed

  Quality Improvement Project - "My Logbook! - I Know my Way Around!"; ("Mein Logbuch - Ich Kenne Mich Aus!")

  NCT04474678· Medical University of Vienna· Source

• Completed

  Study of Early Relapsed, Lenalidomide-refractory Subjects Eligible for Carfilzomib Triplet

  NCT04191616· Phase 2· Amgen· Source

• Terminated

  A Study of Atezolizumab in Combination With Cabozantinib Compared to Cabozantinib Alone in Participants With Advanced Renal Cell Carcinoma After Immune Checkpoint Inhibitor Treatment

  NCT04338269· Phase 3· Hoffmann-La Roche· Source

• Completed

  Physical Training in Glioblastoma Patients During Cytotoxic Therapy

  NCT05015543· University Hospital Muenster· Source

• Completed

  Long-term Safety and Efficacy Study of Lebrikizumab (LY3650150) in Participants With Moderate-to-Severe Atopic Dermatitis (ADjoin)

  NCT04392154· Phase 3· Eli Lilly and Company· Source

• Terminated

  A Study in Patients with a Descending TAA or PAU Treated with the E-nya Thoracic Stent Graft System

  NCT04381507· JOTEC GmbH· Source

• Completed

  Rucaparib MAintenance After Bevacizumab Maintenance Following Carboplatin Based First Line Chemotherapy in Ovarian Cancer Patients

  NCT04227522· Phase 3· North Eastern German Society of Gynaecological Oncology· Source

• Completed

  CARDIO-TTRansform: A Study to Evaluate the Efficacy and Safety of Eplontersen (Formerly Known as ION-682884, IONIS-TTR-LRx and AKCEA-TTR-LRx) in Participants With Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM)

  NCT04136171· Phase 3· Ionis Pharmaceuticals, Inc.· Source

• Completed

  Study of Pembrolizumab (MK-3475) Versus Placebo in Participants With Esophageal Carcinoma Who Are Receiving Chemotherapy and Radiation Therapy (MK-3475-975/KEYNOTE-975)

  NCT04210115· Phase 3· Merck Sharp & Dohme LLC· Source

• Terminated

  PRO-MERIT (Prostate Cancer Messenger RNA Immunotherapy)

  NCT04382898· Phase 1/2· BioNTech SE· Source

• Completed

  A Study to Assess the Long-term Safety and Efficacy of ATB200/AT2221 in Adult Subjects With Late-Onset Pompe Disease (LOPD)

  NCT04138277· Phase 3· Amicus Therapeutics· Source

• Completed

  A Study of JNJ-67856633 in Participants With Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)

  NCT03900598· Phase 1· Janssen Research & Development, LLC· Source

• Completed

  Platinum-based Chemotherapy With Atezolizumab and Niraparib in Patients With Recurrent Ovarian Cancer

  NCT03598270· Phase 3· Grupo Español de Investigación en Cáncer de Ovario· Source

• Completed

  Atezolizumab With Bevacizumab and Chemotherapy vs Bevacizumab and Chemotherapy in Early Relapse Ovarian Cancer

  NCT03353831· Phase 3· AGO Research GmbH· Source

• Completed

  Study Investigating the Efficacy of Crenolanib With Chemotherapy vs Chemotherapy Alone in R/R FLT3 Mutated AML

  NCT03250338· Phase 3· Arog Pharmaceuticals, Inc.· Source

• Completed

  Study of 177Lu-PSMA-617 In Metastatic Castrate-Resistant Prostate Cancer

  NCT03511664· Phase 3· Endocyte· Source

• Completed

  Ibrutinib and Standard Immuno-Chemotherapy in Younger, High-Risk Patients With Diffuse Large B-Cell Lymphoma

  NCT03399513· Phase 2· University Hospital Muenster· Source

• Completed

  A Study to Assess the Safety and Efficacy of Risankizumab for Maintenance in Moderate to Severe Plaque Type Psoriasis ( LIMMITLESS )

  NCT03047395· Phase 3· AbbVie· Source

• Completed

  Impact of Remission Induction Chemotherapy Prior to Allogeneic SCT in Relapsed and Poor-response Patients With AML

  NCT02461537· Phase 3· DKMS gemeinnützige GmbH· Source

• Completed

  A Study of the Effectiveness and Safety of Nivolumab Compared to Bevacizumab and of Nivolumab With or Without Ipilimumab in Glioblastoma Patients

  NCT02017717· Phase 3· Bristol-Myers Squibb· Source

• Completed

  R-CHOP + R-HAD vs R-CHOP Followed by Maintenance Lenalidomide + Rituximab vs Rituximab for Older Patients With MCL

  NCT01865110· Phase 3· The Lymphoma Academic Research Organisation· Source

• Completed

  Pancreatic Carcinoma: Chemoradiation Compared With Chemotherapy Alone After Induction Chemotherapy

  NCT01827553· Phase 3· University of Erlangen-Nürnberg Medical School· Source

Conditions

Diseases this institution publishes on or runs trials for.

• Multiple sclerosis55 works · 2 trials
• Atopic dermatitis (eczema)34 works · 5 trials
• Sarcoma26 works · 2 trials
• Diffuse large B-cell lymphoma16 works · 1 trial
• Liver cirrhosis14 works · 11 trials
• Endometriosis14 works · 0 trials
• Myasthenia gravis13 works · 2 trials
• Endometrial cancer13 works · 0 trials
• Hodgkin lymphoma13 works · 1 trial
• Amyloidosis12 works · 3 trials
• Vitiligo10 works · 0 trials
• Dilated cardiomyopathy8 works · 0 trials
• Ventricular tachycardia8 works · 1 trial
• Down syndrome7 works · 0 trials
• Fabry disease6 works · 1 trial
• Alopecia areata6 works · 0 trials
• Primary biliary cholangitis4 works · 0 trials
• Dermatomyositis and polymyositis (myositis)4 works · 0 trials